在接受核苷（酸）类似物治疗的慢性乙型肝炎患者中，血清IP-10升高与聚乙二醇干扰素α反应相关。
Serum IP-10 increase correlated with PEG-IFNα response in nucleot(s)ide analogs-treated patients with chronic hepatitis B.
作者信息
Wang Wen-Xin, Li Xiaoyan, Jin Xue-Yuan, Jia Rui, Wang Hong-Min, Zhou Shuang-Nan, Zhang Xin, Gao Ying-Ying, Wang Fu-Sheng, Fu Junliang
机构信息
Peking University 302 Clinical Medical School, Beijing 100039, China.
Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China.
出版信息
ILIVER. 2024 Jul 29;3(3):100107. doi: 10.1016/j.iliver.2024.100107. eCollection 2024 Sep.
BACKGROUND AND AIMS
To investigate the association between serum IP-10 and HBsAg levels in chronic hepatitis B (CHB) patients previously treated with nucleot(s)ide analogs (NAs) followed by combined treatment with an NA and pegylated interferon alpha (PEG-IFNα).
METHODS
Ninety-nine patients with serum levels of HBsAg <3000 IU/mL and HBV DNA <20 IU/mL who received prior NA treatment were enrolled. Participants were administered either NA monotherapy (NA group) or combination therapy with PEG-IFNα (Add-on group). Laboratory indicators and IP-10 levels were assessed in serial peripheral blood samples collected at 12- and 24-week intervals. The outcome of this study was a loss or >1 log IU/mL decline in serum HBsAg.
RESULTS
After 48 weeks of antiviral therapy, none of the 27 NA group patients and 15 of the 72 Add-on group patients achieved HBsAg loss. Baseline serum HBsAg and IP-10 levels were equivalent across both groups. The combination treatment led to a decrease in serum HBsAg levels and an early increase in IP-10 levels. Furthermore, a moderate increase in IP-10 levels at weeks 12 or 24 was correlated with loss and decline of HBsAg in the Add-on group. Receiver operating characteristic curve and regression analyses demonstrated that a moderate increase in serum IP-10 levels at weeks 12 or 24 was predictive of HBsAg loss and decline in the Add-on group ( < 0.05).
CONCLUSION
An early and moderate increase in the serum IP-10 level was correlated with responses to PEG-IFNα among patients with CHB treated with NAs.
背景与目的
探讨既往接受核苷（酸）类似物（NA）治疗后再联合NA与聚乙二醇化干扰素α（PEG-IFNα）治疗的慢性乙型肝炎（CHB）患者血清IP-10与HBsAg水平之间的关联。
方法
纳入99例血清HBsAg水平<3000 IU/mL且HBV DNA水平<20 IU/mL且既往接受过NA治疗的患者。参与者接受NA单药治疗（NA组）或联合PEG-IFNα治疗（联合治疗组）。在每隔12周和24周采集的系列外周血样本中评估实验室指标和IP-10水平。本研究的结局为血清HBsAg丢失或下降>1 log IU/mL。
结果
抗病毒治疗48周后，NA组27例患者均未实现HBsAg丢失，联合治疗组72例患者中有15例实现HBsAg丢失。两组的基线血清HBsAg和IP-10水平相当。联合治疗导致血清HBsAg水平下降以及IP-10水平早期升高。此外，联合治疗组第12周或24周时IP-10水平适度升高与HBsAg丢失和下降相关。受试者工作特征曲线和回归分析表明，联合治疗组第12周或24周时血清IP-10水平适度升高可预测HBsAg丢失和下降（P<0.05）。
结论
在接受NA治疗的CHB患者中，血清IP-10水平早期适度升高与对PEG-IFNα的反应相关。
Zotero 插件